Pdt Partners, LLC Exelixis, Inc. Transaction History

Pdt Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $326,567 - $434,719	-19,176 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $730,255 - $1.01 Million	-46,102 Reduced 70.62%	19,176 $351,000
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $211,900 - $274,820	13,000 Added 24.87%	65,278 $1.38 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $938,390 - $1.34 Million	52,278 New	52,278 $953,000
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $753,359 - $981,882	-36,447 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $599,917 - $999,376	36,447 New	36,447 $865,000

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.35B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.